Interní Med. 2016; 18(5): 242-244

Lipertance® – first fixed triple combination of atorvastatin, perindopril arginine, and amlodipine

prof. MUDr. Jiří Widimský jr., CSc.
Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika 1. LF UK a VFN v Praze

The article briefly introduces a novel fixed triple combination of the hypolipidaemic drug atorvastatin and two antihypertensives: perindopril arginine and amlodipine. Because of the frequent co-occurrence of hypertension and dyslipidaemia, this combination can be of benefit and useful in a large number of patients. The use of this combination can improve compliance with the pharmacological treatment of hypertension and dyslipidaemia.

Keywords: hypertension, dyslipidaemia, fixed combination, adherence

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Lipertance® – first fixed triple combination of atorvastatin, perindopril arginine, and amlodipine. Interní Med. 2016;18(5):242-244.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gupta et al Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010 Feb; 55(2): 399-407. Go to original source... Go to PubMed...
    2. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patiens who were switched from fixed-dose to free-combination antihypertensive therapy. P and T, November 2008; 33(11): 652-665.
    3. Filipovský J, Widimský J jr., Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze-verze 2012. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2012; 58(10): 785-801. Go to PubMed...
    4. SPC přípravku LIPERTANCE 2016.
    5. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
    6. Poulter NR fot the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    7. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential Impact of Blood Pressure - Lowering Drugs on Central Aortic Pressure and Clinical Outcomes. Circulation 2006; 113(9): 1213-1225. Go to original source... Go to PubMed...
    8. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practise. Results from the STRONG Prospective, Observational, Multicenter study. Am J Cardiovasc. Drugs 2009; 9(3): 135-142. Go to original source... Go to PubMed...
    9. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Medicine 2009; 122: 290-300. Go to original source... Go to PubMed...
    10. Ferrari R. Optimizing the treatment of hypertension and stable coronary Artury disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr. Med. Res and Opin. 2008; 24(12): 3543-3557. Go to original source... Go to PubMed...
    11. Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patiens with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006; 8(8): 571-581. Go to original source... Go to PubMed...
    12. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011; 27(4): 821-833. Go to original source... Go to PubMed...
    13. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.